Novel Kv1.3 blockers for immunosuppression: WO2012155199

被引：2
|
作者：
William Nguyen [1 ]
机构：
[1] Scripps Res Inst, Dept Mol Therapeut, Jupiter, FL USA
来源：
EXPERT OPINION ON THERAPEUTIC PATENTS | 2013年 / 23卷 / 11期
关键词：
autoimmune disorder; Kv1.3; MS; potassium channel; psoriasis; rheumatoid arthritis; GATED POTASSIUM CHANNEL; MEMORY T-CELLS; AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; ION-CHANNEL; K+ CHANNELS; DERIVATIVES; IMMUNOMODULATION; KHELLINONE; ACTIVATION;
D O I：
10.1517/13543776.2013.831072
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
A recent patent application from Bionomics/Merck Serono describes novel compounds as blockers of the voltage-gated Kv1.3 ion channel. The blockade of this channel shows great promise as a new therapeutic target for the treatment of autoimmune disorders such as multiple sclerosis, psoriasis, diabetes and rheumatoid arthritis. The generic claim of this patent refers to a new chemotype of Kv1.3 blockers based on an amide core with potent IC50's which are potentially within the nanomolar range. This article briefly reviews the chemistry and biology found in the patent and compares it with previous discoveries in the field.
引用
收藏
页码：1511 / 1516
页数：6
相关论文
共 50 条
  • [11] Identification of novel Kv1.3 blockers using a fluorescent cell-based ion channel assay
    Slack, M
    Kirchhoff, C
    Moller, C
    Winkler, D
    Netzer, R
    JOURNAL OF BIOMOLECULAR SCREENING, 2006, 11 (01) : 57 - 64
  • [12] An alternative to conventional immunosuppression:: Small-molecule inhibitors of Kv1.3 channels
    Damjanovich, S
    Gáspár, R
    Panyi, G
    MOLECULAR INTERVENTIONS, 2004, 4 (05) : 250 - +
  • [13] The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression
    Lam, Jenny
    Wulff, Heike
    DRUG DEVELOPMENT RESEARCH, 2011, 72 (07) : 573 - 584
  • [14] Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease
    Chandy, K. George
    Norton, Raymond S.
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2017, 38 : 97 - 107
  • [15] Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate
    Nguyen, William
    Howard, Brittany L.
    Jenkins, David P.
    Wulff, Heike
    Thompson, Philip E.
    Manallack, David T.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (23) : 7106 - 7109
  • [16] Transmembrane biogenesis of Kv1.3
    Tu, L
    Wang, J
    Helm, A
    Skach, WR
    Deutsch, C
    BIOCHEMISTRY, 2000, 39 (04) : 824 - 836
  • [17] Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone
    Hye Sook Ahn
    Sung Eun Kim
    Hyun-Jong Jang
    Myung-Jun Kim
    Duck-Joo Rhie
    Shin-Hee Yoon
    Yang-Hyeok Jo
    Myung-Suk Kim
    Ki-Wug Sung
    Seong Yun Kim
    Sang June Hahn
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2007, 374 : 305 - 309
  • [18] Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone
    Ahn, Hye Sook
    Kim, Sung Eun
    Jang, Hyun-Jong
    Kim, Myung-Jun
    Rhie, Duck-Joo
    Yoon, Shin-Hee
    Jo, Yang-Hyeok
    Kim, Myung-Suk
    Sung, Ki-Wug
    Kim, Seong Yun
    Hahn, Sang June
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2007, 374 (04) : 305 - 309
  • [19] Design and synthesis of human T cell Kv1.3 potassium channel blockers.
    Lew, A
    Chamberlin, AR
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 218 : U917 - U917
  • [20] Design and characterization of a novel structural class of Kv1.3 inhibitors
    Hendrickx, Louise Antonia
    Dobricic, Vladimir
    Toplak, Zan
    Peigneur, Steve
    Masic, Lucija Peterlin
    Tomasic, Tihomir
    Tytgat, Jan
    BIOORGANIC CHEMISTRY, 2020, 98
12345